Vertex Pharmaceuticals reported insider transactions and a restricted‑stock vesting event. The filing lists 1,182 common shares under "Securities To Be Sold" tied to Restricted Stock Vesting on 02/17/2026 as "Issuer" compensation. The filing also records sales by Mark E. Bunnage: 23 shares on 12/29/2025 (10,649.00), 2,021 shares on 02/11/2026 (930,529.03), and 2,437 shares on 02/17/2026 (1,192,814.02).
Vertex Pharmaceuticals filed a Form 144 reporting proposed and recent transactions in its common stock. The filing lists 817 shares to be sold on 02/17/2026 tied to restricted stock vesting, and prior sales by E Morrey Atkinson of 1,751 shares on 02/11/2026 and 2,031 shares on 02/17/2026.
Vertex Pharmaceuticals (VRTX) insider Mark Bunnage filed a notice to sell 2,437 shares of Vertex common stock through Fidelity Brokerage Services on NASDAQ, with an aggregate market value of $1,192,814.02, with an approximate sale date of February 17, 2026.
The shares to be sold were acquired on February 13, 2026 via restricted stock vesting from the issuer as compensation. Over the prior three months, Bunnage sold 2,021 Vertex common shares on February 11, 2026 for gross proceeds of $930,529.03 and 23 shares on December 29, 2025 for $10,649.00.
An affiliate of VRTX, identified as Ourania Tatsis, has filed a notice to sell 609 shares of common stock through Fidelity Brokerage Services on NASDAQ around 02/17/2026. These shares were acquired on 02/13/2026 via restricted stock vesting as compensation from the issuer.
The filing also lists recent sales over the prior three months. On 12/03/2025 and 01/07/2026, Tatsis sold 4,500 common shares each, with gross proceeds of 2024955.40 and 2137455.00. Additional sales on 02/11/2026 and 02/13/2026 covered 466 and 1,500 shares, with proceeds of 214560.38 and 749992.02.
An affiliated shareholder has filed notice of an intended sale of 2,476 shares of common stock through Fidelity Brokerage Services LLC on or around February 17, 2026 on the NASDAQ. The filing lists an aggregate market value of $1,211,902.96 for these shares, compared with 254,034,190 shares outstanding.
The shares to be sold were acquired on February 13, 2026 through restricted stock vesting from the issuer as compensation. The notice also details prior sales in the last three months by Jonathan P. Biller, including several smaller common‑stock transactions.
Vertex Pharmaceuticals executive Edward Atkinson has filed a notice of proposed share sales under Rule 144. The filing covers the planned sale of 2,031 shares of Vertex common stock through Fidelity Brokerage Services LLC on or about 02/17/2026 on NASDAQ, with an aggregate market value of 994093.26 at the time of the notice.
The 2,031 shares to be sold were acquired on 02/13/2026 via restricted stock vesting from the issuer as compensation. Over the past three months, Atkinson has already sold 2,500 Vertex common shares on 11/17/2025 for gross proceeds of 1086450.00, and 1,751 shares on 02/11/2026 for gross proceeds of 806212.93. The filing also notes that the seller represents not being aware of undisclosed material adverse information about the company.
Vertex Pharmaceuticals describes a broad rare-disease and specialty portfolio in its annual report, led by cystic fibrosis medicines, the gene-editing therapy CASGEVY for severe sickle cell disease and transfusion‑dependent beta thalassemia, and JOURNAVX for moderate‑to‑severe acute pain in adults.
The company highlights a deep late‑stage pipeline, including povetacicept for IgA nephropathy and primary membranous nephropathy, inaxaplin for APOL1‑mediated kidney disease, zimislecel cell therapy for type 1 diabetes, and suzetrigine for diabetic peripheral neuropathic pain. Vertex reports strong global commercialization, extensive intellectual‑property protection, and ongoing investment in manufacturing capacity and strategic deals such as the Alpine acquisition.
A shareholder filed a notice of proposed sale of 988 shares of common stock, to be sold through Fidelity Brokerage Services LLC on or about 02/13/2026 on NASDAQ. The filing notes that 253,718,831 shares of the class were outstanding.
The shares to be sold were acquired via restricted stock vesting from the issuer as compensation, with 347 shares vesting on 10/01/2025 and 641 shares vesting on 02/10/2026. The shareholder, Jonathan Biller, previously sold 347 shares on 12/03/2025 for gross proceeds of 155,803.00 and 1,925 shares on 02/11/2026 for gross proceeds of 886,327.75.
Vertex Pharmaceuticals has an insider planning a modest stock sale. A person associated with Vertex intends to sell 266 shares of common stock through Fidelity Brokerage Services on the NASDAQ, with an aggregate market value of 133000.00, around 02/13/2026.
The 266 shares were acquired on 05/01/2024 through restricted stock vesting as compensation from the issuer. Vertex had 253,718,831 shares of common stock outstanding, which is a baseline figure for the company’s total share count.
Vertex Pharmaceuticals shareholder Ourania Tatsis filed a Form 144 notice to sell 1,500 shares of Vertex common stock, with an aggregate market value of $749,992.02, through Fidelity Brokerage Services on NASDAQ around February 13, 2026.
The filing indicates 253,718,831 Vertex common shares outstanding. The 1,500 shares to be sold trace to restricted stock that vested as compensation in February 2021, in lots of 1,448 and 52 shares acquired from the issuer.
Over the past three months, Tatsis has sold additional Vertex common shares, including 4,500 shares on December 3, 2025 for gross proceeds of $2,024,955.40, 4,500 shares on January 7, 2026 for $2,137,455.00, and 466 shares on February 11, 2026 for $214,560.38.